Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer

Cellular Physiology and Biochemistry

Volumn 32, Issue 5, 2013, Pages 1528-1540

  Sun, Hongzan ^a   Xin, Jun ^a   Lu, Zaiming ^a   Wang, Ning ^a   Liu, Ning ^a   Guo, Qiyong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Carboplatin; Cervical cancer; Cisplatin; E2F; ERK1 2; Mdm2; MiR 34a; MiR 605; MiRNAs; Neoadjuvant chemotherapy (NAC); P53; Paclitaxel; TAB1

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CARBOPLATIN; CISPLATIN; MICRORNA; MICRORNA 34A; MICRORNA 605; ONCOPROTEIN; PACLITAXEL; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LAPAROSCOPIC SURGERY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTADIENES; CISPLATIN; DISEASE-FREE SURVIVAL; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; HYSTERECTOMY; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; UTERINE CERVICAL NEOPLASMS;

EID: 84890755848     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000356590     Document Type: Article

References (49)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J: Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-2686.
2. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Sideri M, Pecorelli S: Carcinoma of the corpus uteri. J Epidemiol Biostat 2001;61:47-86.
3. Parkin DM, Bray F, Ferlay J, Prisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Fu Y, Reagan J: Pathology of the Uterine Cervix, Vagina and Vulva. Major Problems in Pathology. Philadelphia, W.B. Saunders and Co, 1989, pp288-335.
5. Pisani P, Bray F, Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.
6. Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A, Zehbe I: The role of TP53 in Cervical carcinogenesis. Hum Mutat 2003;21:307-312.
7. Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, Mackay H, Amir E, Liu G: p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and metaanalysis. Clin Cancer Res 2012;18:6407-6415.
8. Arends MJ, Buckley CH, Wells M: Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 1998;51:96-103.
9. Yaziji H, Gown AM: Immunohistochemical analysis of gynecologic tumors. Int J Gynecol Pathol 2001;20:64-78.
10. Tan S, de Vries EG, van der Zee AG, de Jong S: Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets 2012;12:170-184.
11. Adewole IF, Benedet JL, Crain BT, Follen M: Evolving a strategic approach to cervical cancer control in Africa. Gynecol Oncol 2005;99:S209-212.
12. Emembolu JO, Ekwempu CC: Carcinoma of the cervix uteri in Zaria: etiological factors. Int J Gynaecol Obstet 1988;26:265-269.
13. Hacker NF, Friedlander ML: Cervical cancer; in Berek JS, Hacker NF (eds): Berek & Hacker's gynecologic oncology. 5th ed. Philadelphia , Lippincott Williams & Wilkins, 2010, pp341-395.
14. Bidus MA, Elcas JC: Cervical and vaginal cancer; in Berek JS, Novak E (eds): Berek & Novak's gynecology. 14th ed. Philadelphia, Lippincott Williams & Wilkins, 2007, pp1403-1456.
15. Boyce J, Fruchter RG, Nicastri AD, Ambiavagar PC, Reinis MS, Nelson JH Jr: Prognostic factors in stage I carcinoma of the cervix. Gynecol Oncol 1981;12:154-165.
16. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F: Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38:352-357.
17. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26:731-743.
18. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB: MicroRNA-34 mediates ARdependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 2008;7:1288-1296.
19. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745-752.
20. Barak Y, Juven T, Haffner R, Oren M: mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-468.
21. Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-2908.
22. Xiao J, Lin H, Luo X, Luo X, Wang Z: miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J 2011;30:524-532.
23. Su XY, Yin HT, Li SY, Huang XE, Tan HY, Dai HY, Shi FF: Intervention effects of nedaplatin and cisplatin on proliferation and apoptosis of human tumour cells in vitro. Asian Pac J Cancer Prev 2012;13:4531-4536.
24. Zhu Y, Regunath K, Jacq X, Prives C: Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry. Genes Dev 2013;27:1739-1751.
25. Hennequin C, Giocanti N, Favaudon V: Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996;56:1842-1850.
26. Siemer S, Ornskov D, Guerra B, Boldyreff B, Issinger OG: Determination of mRNA, and protein levels of p53, MDM2 and protein kinase CK2 subunits in F9 cells after treatment with the apoptosis-inducing drugs cisplatin and carboplatin. Int J Biochem Cell Biol 1999;31:661-670.
27. Huang H, Huang SY, Chen TT, Chen JC, Chiou CL, Huang TM: Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells. J Cell Biochem 2004;91:756-765.
28. Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Fukamachi T, Tada Y, Takiguchi Y, Tatsumi K, Shimada H, Hiroshima K, Kobayashi H, Tagawa M: Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53expression levels. PLoS One 2013;8:e60297.
29. Takahashi M, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Kamazawa S, Sato S, Akeshima R, Terakawa N: Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 2000;36:1863-1868.
30. DeHaan RD, Yazlovitskaya EM, Persons DL: Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemother Pharmacol 2001;48:383-388.
31. Persons DL, Yazlovitskaya EM, Pelling JC: Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 2000;275:35778-35785.
32. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-262.
33. Iwasaka T, Kamura T, Yokoyama M, Matsuo N, Nakano H, Sugimori H: Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: a comparison with effects of adjuvant radiotherapy. Obstet Gynecol 1998;91:977-981.
34. Takeshima N, Umayahara K, Fujiwara K, Hirai Y, Takizawa K, Hasumi K: Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate-and high-risk stage IB-IIA cervical cancer. Gynecol Oncol 2006;103:618-622.
35. Tattersall MH, Ramirez C, Coppleson M: A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases. Gynecol Oncol 1992;46:176-181.
36. Alberts DS, Garcia D, Mason-Liddil N: Cisplatin in advanced cancer of the cervix: an update. Semin Oncol 1991;18:11-24.
37. Runowicz CD, Wadler S, Rodriguez-Rodriguez L, Litwin P, Shaves M, O'Hanlan KA, Goldberg GL, Tomaino CT, Byrnes R: Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma. Gynecol Oncol 1989;34:395-401.
38. Al-Saleh E, Hoskins PJ, Pike JA, Swenerton KD: Cisplatin/ etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma. Gynecol Oncol 1997;64:468-472.
39. Olive ST, Kiser WR: Diagnosis of appendicitis. J Am Board Fam Pract 1996;9:306-307.
40. Bonomi P, Blessing J, Ball H, Hanjani P, DiSaia PJ: A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 1989;34:357-359.
41. Namkoong SE, Park JS, Kim JW, Bae SN, Han GT, Lee JM, Jung JK, Kim SJ: Comparative study of the patients with locally advanced stages I and II cervical cancer treated by radical surgery with and without preoperative adjuvant chemotherapy. Gynecol Oncol 1995;59:136-142.
42. Alberts DS, Kronmal R, Baker LH, Stock-Novack DL, Surwit EA, Boutselis JG, Hannigan EV: Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. J Clin Oncol 1987;5:1791-1795.
43. Katsumata N, Yoshikawa H, Hirakawa T, Saito T, Kuzuya K, Fujii T, Hiura M, Tsunematsu R, Fukuda H, Kamura T: Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer. ASCO Annu Meet Proc 2006;24: abs. 5013.
44. Monk BJ, Huang HQ, Cella D, Long HJ 3rd: Gynecologic Oncology Group Study: Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4617-4625.
45. Wheate NJ, Walker S, Craig GE, Oun R: The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010;39:8113-8127.
46. Fujita Y, Seki N, Inoue K, Miyazawa T, Eguchi K: A comparison of cisplatin and carboplatin: a short review. West Indian Med J 2010;59:115.
47. Natarajan G, Malathi R, Holler E: Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodi ammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol 1999;58:1625-1629.
48. Jordan MA, Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265.
49. Fuchs, David A and Johnson, Randall K: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978;62:1219-1222.